Innate Pharma (IPHYF) Total Debt (2017 - 2025)

Innate Pharma's Total Debt history spans 9 years, with the latest figure at $26.3 million for Q4 2025.

  • For Q4 2025, Total Debt fell 20.67% year-over-year to $26.3 million; the TTM value through Dec 2025 reached $26.3 million, down 20.67%, while the annual FY2025 figure was $26.3 million, 21.67% down from the prior year.
  • Total Debt reached $26.3 million in Q4 2025 per IPHYF's latest filing, down from $33.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $50.6 million in Q4 2021 to a low of $26.3 million in Q4 2025.
  • Average Total Debt over 5 years is $39.2 million, with a median of $42.9 million recorded in 2023.
  • Peak YoY movement for Total Debt: surged 122.44% in 2021, then dropped 22.84% in 2024.
  • A 5-year view of Total Debt shows it stood at $50.6 million in 2021, then fell by 14.85% to $43.1 million in 2022, then dropped by 0.43% to $42.9 million in 2023, then decreased by 22.84% to $33.1 million in 2024, then dropped by 20.67% to $26.3 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Total Debt are $26.3 million (Q4 2025), $33.1 million (Q4 2024), and $42.9 million (Q4 2023).